Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results-Reference-Cited by-同舟云学术

Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results

Published:2020-10-22 Issue:8 Volume:4 Page:1324-1330
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

John M. Joseph¹,Chakrabarti Prantar²,Apte Shashikant³,Bhattacharyya Maitreyee⁴,S. Chandrakala⁵,Hansen Trine⁶,Kolla Rohan⁷,Ross Cecil⁸,Seth Tulika⁹,Siddharthan Neeraj¹⁰,Abraham Aby¹¹

Affiliation:

1. Department of Clinical Haematology, Haemato‐Oncology, & Bone Marrow (Stem Cell) Transplant Unit Christian Medical College and Hospital Ludhiana India

2. Department of Hematology NRS Medical College Kolkata India

3. Department of Hematology and Bone Marrow Transplantation Sahyadri Specialty Hospital Pune India

4. Department of Hematology Calcutta Medical College Kolkata India

5. Department of Haematology KEM Hospital Mumbai India

6. Novo Nordisk A/S Søborg Denmark

7. Novo Nordisk India Bangalore India

8. St Johns Medical College Hospital Bangalore India

9. Department of Haematology All India Institute of Medical Sciences New Delhi India

10. Department of Clinical Haematology Amrita Institute of Medical Sciences Kochi India

11. Department of Hematology Christian Medical College Vellore India

Funder

Novo Nordisk

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12441

Reference27 articles.

1. Blood clotting factor VIII: from evolution to therapy;Orlova NA;Acta Naturae,2013

2. World Federation of Hemophilia.Report on Annual Global Survey 2014. p. 34–6 48. [Accessed November 02 2019].

3. Anti‐hemophilic factor (recombinant), plasma/albumin‐free method (octocog‐alpha; ADVATE) in the management of hemophilia A;Shapiro AD;Vasc Health Risk Manag,2007

4. Novo Eight (Anti‐hemophilic factor [recombinant] prescribing information). Novo Nordisk Bagsvaerd Denmark; 2011. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/002719/WC500157553.pdf. 2014. p. 4 12. [Accessed December 11 2019]

5. Epidemiology & social costs of haemophilia in India;Kar A;Indian J Med Res,2014